Sung-Bae Kim, Professor at Asan Medical Center, Institute for Innovative Cancer Research, shared on X:
“Our OPTIMAL trial is now in print in the July 2026, Annals of Oncology.
Oral paclitaxel (DHP107) is non-inferior to weekly IV paclitaxel in HER2− metastatic breast cancer – same efficacy, less neuropathy, no infusion.
Now MFDS-approved in Korea (weekly).”
Hope Rugo, Professor of Medicine and Director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, shared this post, adding:
“Great to see this in print! Congrats! Our US phase II OPERA trial also published this year with DHP107 showing non-inferiority to IV paclitaxel in mBC; complementary to Optimal.”
Title: OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer
Authors: Hope S. Rugo, T. J. Pluard, P. Sharma, M. Melisko, G. Al-Jazayrly, Y. Ji, N. Vidula, J. Ellerton, M. Smakal, M. Zimovjanova, D. Weng
Read the full article.
You can also read:
Germline Multigene Testing May Identify Higher-Risk Invasive Lobular Breast Cancer
